Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
An announcement from Corbus Pharmaceuticals ( (CRBP) ) is now available.
On October 30, 2025, Corbus Pharmaceuticals announced an underwritten public offering of common stock and pre-funded warrants, aiming to raise approximately $70.5 million. The proceeds are intended to fund clinical development and general corporate purposes. The offering, managed by Jefferies and Piper Sandler, is expected to close around November 3, 2025, subject to customary conditions. This move is part of Corbus’ strategy to strengthen its financial position and advance its pipeline in the competitive oncology and obesity sectors.
The most recent analyst rating on (CRBP) stock is a Buy with a $39.00 price target. To see the full list of analyst forecasts on Corbus Pharmaceuticals stock, see the CRBP Stock Forecast page.
Spark’s Take on CRBP Stock
According to Spark, TipRanks’ AI Analyst, CRBP is a Neutral.
Corbus Pharmaceuticals’ overall stock score is driven by severe financial challenges, including no recent revenue and high net losses, which significantly weigh down its score. However, technical indicators suggest some short-term positive momentum. The promising Phase 1 trial results provide a potential catalyst in the biotechnology field, offering some positive outlook despite the current financial difficulties.
To see Spark’s full report on CRBP stock, click here.
More about Corbus Pharmaceuticals
Corbus Pharmaceuticals Holdings, Inc. is a company focused on oncology and obesity, with a diversified portfolio aimed at addressing serious illnesses through innovative scientific approaches. The company’s pipeline includes CRB-701, a next-generation antibody drug conjugate targeting Nectin-4 on cancer cells, CRB-601, an anti-integrin monoclonal antibody blocking TGFβ activation on cancer cells, and CRB-913, a CB1 inverse agonist for obesity treatment. Corbus is headquartered in Norwood, Massachusetts.
Average Trading Volume: 254,596
Technical Sentiment Signal: Hold
Current Market Cap: $148.9M
Find detailed analytics on CRBP stock on TipRanks’ Stock Analysis page.